Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan

References

• International Agency for Research on Cancer. Globocan 2020. [accessed 2020 Jan 11]. http://gco.iarc.fr/ (Japan: https://gco.iarc.fr/today/data/factsheets/populations/392-japan-fact-sheets.pdf.)
   Google Scholar
• Eto K, Ida S, Watanabe M, Baba H. Treatment strategy for metastatic gastric cancer in Japan. J Cancer Metastasis Treat. 2018;4(5):23. doi:10.20517/2394-4722.2017.73.
   Google Scholar
• Ministry of Health, Labour and Welfare. Cancer control promotion basic plan. [ accessed 2021 Jan, 11]. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000183313.html.
   Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202–209. doi:10.1038/nature13480.
   PubMed Web of Science ®Google Scholar
• Eto S, Yoshikawa K, Nishi M, Higashijima J, Tokunaga T, Nakao T, Kashihara H, Takasu C, Iwata T, Shimada M . Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 2016;19 (2):466–471 doi:10.1007/s10120-015-0519-7.
   PubMed Web of Science ®Google Scholar
• Liu YX, Wang XS, Wang YF, Hu XC, Yan JQ, Zhang YL, Wang W, Yang R-J, Feng Y-Y, Gao S-G, et al. Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. Onco Targets Ther. 2016;9:2649–2654. doi:10.2147/OTT.S102616.
   PubMedGoogle Scholar
• Tamura T, Ohira M, Tanaka H, Muguruma K, Toyokawa T, Kubo N, Sakurai K, Amano R, Kimura K, Shibutani M, et al. Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res. 2015;35(10):5369–5376.
   PubMed Web of Science ®Google Scholar
• Wu Y, Cao D, Qu L, Cao X, Jia Z, Zhao T, Wang Q, Jiang J. PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. Oncotarget. 2017;8(38):64066–64082. doi:10.18632/oncotarget.19318.
   PubMedGoogle Scholar
• Kim JW, Nam KH, Ahn SH, Park DJ, Kim HH, Kim SH, Chang H, Lee J-O, Kim YJ, Lee HS, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016;19(1):42–52. doi:10.1007/s10120-014-0440-5.
   PubMed Web of Science ®Google Scholar
• Gu L, Chen M, Guo D, Zhu H, Zhang W, Pan J, Zhong X, Li X, Qian H, Wang X . PD-L1 and gastric cancer prognosis: a systematic review and meta-analysis. PLoS One. 2017;12(8):e0182692. doi:10.1371/journal.pone.0182692.
   PubMed Web of Science ®Google Scholar
• Saito R, Abe H, Kunita A, Yamashita H, Seto Y, Fukayama M. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1(+) immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol. 2017;30(3):427–439. doi:10.1038/modpathol.2016.202.
   PubMed Web of Science ®Google Scholar
• Kelly RJ. Immunotherapy for esophageal and gastric cancer. Am Soc Clin Oncol Educ Book. 2017;37(37):292–300. doi:10.1200/EDBK_175231.
   PubMedGoogle Scholar
• Koh J, Ock C-Y, Kim JW, Nam SK, Kwak Y, Yun S, Ahn S-H, Park DJ, Kim H-H, and Kim WH, et al. Clinicopathologic implications of immune classification by PD-L1 expression and CD8-positive tumor-infiltrating lymphocytes in stage II and III gastric cancer patients. Oncotarget. 2017;8(16):26356–26367. doi:10.18632/oncotarget.15465.
   PubMedGoogle Scholar
• Kim DH, Bae GE, Suh KS, Ryuman D, Song KS, Kim JS, Lee SI, and Yeo MK. Clinical significance of tumor and immune cell PD-L1 expression in gastric adenocarcinoma. In Vivo. 2020;34(6):3171–3180. doi:10.21873/invivo.12152.
   PubMed Web of Science ®Google Scholar
• Choi E, Chang MS, Byeon SJ, Jin H, Jung KC, Kim H, Lee KL, Kim W, Park JH, and Kim KH, et al. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas. Diagn Pathol. 2020 ;15(1):69. doi:10.1186/s13000-020-00979-z.
   PubMed Web of Science ®Google Scholar
• Agilent Technologies. Interpretation Manual - Gastric or Gastroesophageal Junction Adenocarcinoma. PD-L1 IHC 22C3 pharmDx is FDA-approved for in vitro diagnostic use. [ accessed 2021 Jan 11]. https://www.agilent.com/cs/library/usermanuals/public/29219_pd-l1-ihc-22C3-pharmdx-gastric-interpretation-manual_us.pdf.
   Google Scholar
• Emancipator K, Huang L, Aurora-Garg D, Bal T, Cohen EEW, Harrington K, Soulières D, Le Tourneau C, Licitra L, and Burtness B, et al. Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Mod Pathol. 2020;34(3):532–541. doi:10.1038/s41379-020-00710-9.
   PubMed Web of Science ®Google Scholar
• Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, Jansson M, Shah S, Hanks D, Wang J, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143(3):330–337. doi:10.5858/arpa.2018-0043-OA
   PubMed Web of Science ®Google Scholar
• Jiang Y, Lo AWI, Wong A, Chen W, Wang Y, Lin L, Xu J. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma. Oncotarget. 2017;8(18):30175–30189. doi:10.18632/oncotarget.15621.
   PubMedGoogle Scholar
• Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, Doi T, Moriwaki T, Kim S-B, Lee S-H, et al. KEYNOTE-181 Investigators. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38(35):4138–4148. doi:10.1200/JCO.20.01888.
   PubMed Web of Science ®Google Scholar
• Shah MA, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, Lordick F, Kim S-B, Tajika M, Kim HT, et al. Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE-180 study. JAMA Oncol. 2019;5(4):546–550. doi:10.1001/jamaoncol.2018.5441
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. KEYTRUDA® (pembrolizumab) FDA prescribing information. [ accessed 2021 Jan 11]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/125514s012lbl.pdf.
   Google Scholar
• Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, Goldberg KB, Keegan P, McKee AE, Pazdur R. FDA approval summary: pembrolizumab for recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist. 2019;24(1):103–109. doi:10.1634/theoncologist.2018-0221.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. [ accessed 2020 Jan 5]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication.
   Google Scholar
• Japanese gastric cancer treatment guidelines. [ accessed 2020 Jan 5]. http://www.jgca.jp/guide_mag.html.
   Google Scholar
• Bang Y-J, Kang Y-K, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, and Jalal SI, et al. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828–837. doi:10.1007/s10120-018-00909-5.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges J-P, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013. doi:10.1001/jamaoncol.2018.0013.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. doi: 10.1016/j.immuni.2013.07.012.
   PubMed Web of Science ®Google Scholar
• Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol. 2019;12(1):54. doi:10.1186/s13045-019-0738-1.
   PubMed Web of Science ®Google Scholar
• Oliveira AF, Bretes L, Furtado I. Review of PD-1/PD-L1 inhibitors in metastatic dMMR/MSI-H colorectal cancer. Front Oncol. 2019;9:396. doi:10.3389/fonc.2019.00396.
   PubMed Web of Science ®Google Scholar
• Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang Y, Zhang Q. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget. 2017;8(19):31347–31354. doi: 10.18632/oncotarget.15532.
   PubMedGoogle Scholar
• Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, Yoshino T, Doi T, Ohtsu A, Ochiai A, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407–415. doi:10.1007/s10120-016-0631-3.
   PubMed Web of Science ®Google Scholar
• Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, et al. Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. Gastric Cancer. 2019;22(1):69–76. doi:10.1007/s10120-018-0843-9.
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang Y-J, Fuchs C, Wyrwicz L, Lee K-W, Kudaba I, Garrido M, Chung HC, and Lee J, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6(10):1571–1580. doi:10.1001/jamaoncol.2020.3370
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang Y-J, Di Bartolomeo M, Mandalà M, Ryu M-H, Fornaro L, Olesiński T, Caglevic C, Chung HC, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi:10.1016/S0140-6736(18)31257-1.
   PubMed Web of Science ®Google Scholar
• Muro K, Fuchs CS, Jang RW-J, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges J-P, and Garrido M, et al. KEYNOTE-059 cohort 1: pembrolizumab (pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+ tumors—Asian subgroup analysis. J Clin Oncol. 2018;36(4_suppl):723. doi:10.1200/JCO.2018.36.4_suppl.723.
   Web of Science ®Google Scholar
• Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–726. doi:10.1016/S1470-2045(16)00175-3.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Cutsem EV, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Salguero HRC, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37(18_suppl):LBA4007. doi:10.1200/JCO.2019.37.18_suppl.LBA4007.
   Web of Science ®Google Scholar
• Morihiro T, Kuroda S, Kanaya N, Kakiuchi Y, Kubota T, Aoyama K, Tanaka T, Kikuchi S, Nagasaka T, Nishizaki M, et al. PD-L1 expression combined with microsatellite instability/CD8+ tumor infiltrating lymphocytes as a useful prognostic biomarker in gastric cancer. Sci Rep. 2019;9(1):4633. doi:10.1038/s41598-019-41177-2.
   PubMedGoogle Scholar
• Kim J-Y, Shin NR, Kim A, Lee H-J, Park W-Y, Kim J-Y, Lee, C-H, Huh, G-Y, Park, DY, et al. Microsatellite instability status in gastric cancer: a reappraisal of its clinical significance and relationship with mucin phenotypes. Korean J Pathol. 2013;47(1):28–35. doi:10.4132/KoreanJPathol.2013.47.1.28.
   PubMedGoogle Scholar
• Lin X, Zhao Y, Song WM, Zhang B. Molecular classification and prediction in gastric cancer. Comput Struct Biotechnol J. 2015;13:448–458. doi:10.1016/j.csbj.2015.08.001.
   PubMed Web of Science ®Google Scholar
• Lorenzi M, Amonkar M, Zhang J, Mehta S,Liaw K-L. Epidemiology of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) in solid tumors: a structured literature review. J Oncol. 2020;20(1807929):1–20. doi:10.1155/2020/1807929.
   Google Scholar
• Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–413. doi:10.1126/science.aan6733.
   PubMed Web of Science ®Google Scholar
• Inoue M. Changing epidemiology of Helicobacter pylori in Japan. Gastric Cancer. 2017;20(S1):3–7. doi:10.1007/s10120-016-0658-5.
   PubMedGoogle Scholar
• Goh LY, Leow AH, Goh KL. Observations on the epidemiology of gastrointestinal and liver cancers in the Asia-Pacific region. J Dig Dis. 2014;15(9):463–468. doi:10.1111/1751-2980.12164.
   PubMed Web of Science ®Google Scholar
• Holokai L, Chakrabarti J, Broda T, Chang J, Hawkins JA, Sundaram N, Wroblewski LE, Peek Jr RM, Wang J, Helmrath M, et al. Increased programmed death-ligand 1 is an early epithelial cell response to helicobacter pylori infection. PLoS Pathog. 2019;15(1):e1007468. doi:10.1371/journal.ppat.1007468.
   PubMed Web of Science ®Google Scholar
• Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16(6):415–419. doi:10.1111/j.1523-5378.2011.00889.x.
   PubMed Web of Science ®Google Scholar
• Tsuda M, Asaka M, Kato M, Matsushima R, Fujimori K, Akino K, Kikuchi S, Lin Y, Sakamoto N. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22(5):e12415. doi:10.1111/hel.12415.
   PubMed Web of Science ®Google Scholar
• Miftahussurur M, Yamaoka Y. Diagnostic methods of Helicobacter pylori infection for epidemiological studies: critical importance of indirect test validation. Biomed Res Int. 2016;2016:4819423. doi:10.1155/2016/4819423.
   PubMed Web of Science ®Google Scholar
• Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–1458. doi:10.1038/s41591-018-0101-z.
   PubMed Web of Science ®Google Scholar
• Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40. doi:10.1016/S0140-6736(21)00797-2.
   PubMed Web of Science ®Google Scholar
• Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019;7(1):24. doi:10.1186/s40425-019-0514-3.
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Randon G, Di Bartolomeo M, Luciani A, Chao J, Smyth EC, Petrelli F. Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials. ESMO Open. 2021;6(1):100036. doi:10.1016/j.esmoop.2020.100036.
   PubMed Web of Science ®Google Scholar
• Kim JH, Park HE, Cho N-Y, Lee HS, Kang GH . Characterisation of PD-L1-positive subsets of microsatellite-unstable colorectal cancers. Br J Cancer. 2016;115(4):490–496. doi:10.1038/bjc.2016.211.
   PubMed Web of Science ®Google Scholar
• Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, Solcia E, Sessa F, Fleitas T, Freeman GJ, Rodig SJ, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers. Oncotarget. 2016;7(22):32925–32932. doi:10.18632/oncotarget.9076.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Marabelle A, Delord J-P, Shapira-Frommer R, Geva R, Peled N, Kim TW, Andre T, Van Cutsem E, Guimbaud R, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. [Abstract]. 2017;35:3071.
   Google Scholar
• Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, Geva R, Gottfried M, Penel N, and Hansen AR, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10. doi:10.1200/JCO.19.02105.
   PubMed Web of Science ®Google Scholar
• Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi:10.1158/1078-0432.CCR-18-4070.
   PubMed Web of Science ®Google Scholar
• Camargo MC, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, Yu J, Sung JJY, Herrera-Goepfert R, Meneses-Gonzalez F, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63(2):236–243. doi:10.1136/gutjnl-2013-304531.
   PubMed Web of Science ®Google Scholar
• Camargo MC, Murphy G, Koriyama C, Pfeiffer RM, Kim WH, Herrera-Goepfert R, Corvalan AH, Carrascal E, Abdirad A, Anwar M, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer. 2011;105(1):38–43. doi:10.1038/bjc.2011.215.
   PubMed Web of Science ®Google Scholar
• Koriyama C, Akiba S, Corvalan A, Carrascal E, Itoh T, Herrera-Goepfert R, Eizuru Y, Tokunaga M. Histology-specific gender, age and tumor-location distributions of Epstein-Barr virus-associated gastric carcinoma in Japan. Oncol Rep. 2004;12(3):543–547.
   PubMed Web of Science ®Google Scholar
• Nishikawa J, Iizasa H, Yoshiyama H, Shimokuri K, Kobayashi Y, Sasaki S, Nakamura M, Yanai H, Sakai K, Suehiro Y, et al. Clinical importance of Epstein-Barr virus-associated gastric cancer. Cancers (Basel). 2018;10(6):167. doi:10.3390/cancers10060167.
   PubMed Web of Science ®Google Scholar
• Nakano H, Saito M, Nakajima S, Saito K, Nakayama Y, Kase K, Yamada L, Kanke Y, Hanayama H, Onozawa H, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Sci Rep. 2021;11(1):1982. doi:10.1038/s41598-021-81667-w.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Q, Ni S, Tan C, Cai X, Huang D, Sheng W . Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. Cancer Med. 2018;7(6):2612–2620. doi:10.1002/cam4.1502.
   PubMed Web of Science ®Google Scholar
• Oki E, Okano S, Saeki H, Umemoto Y, Teraishi K, Nakaji Y, Ando K, Zaitsu Y, Yamashita N, Sugiyama M, et al. Protein expression of programmed death 1 ligand 1 and HER2 in gastric carcinoma. Oncology. 2017;93(6):387–394. doi:10.1159/000479231.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Bang Y-J, Feng-Yi F, Xu JM, Lee K-W, Jiao SC, Chong JL, López-Sanchez RI, Price T, and Gladkov O, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484. doi:10.1007/s10120-014-0402-y.
   PubMed Web of Science ®Google Scholar
• Irkkan C, Balci S, Güler Tezel G, Akinci B, Yalcin B, Güler G. Comparison of clinicopathologic parameters and survivals between Epstein-Barr virus-positive and Her2-positive gastric cancers. Appl Immunohistochem Mol Morphol. 2017;25(9):609–614. doi:10.1097/PAI.0000000000000353.
   PubMedGoogle Scholar
• Zhang M, Dong Y, Liu H, Wang Y, Zhao S, Xuan Q, Wang Y, Zhanga Q, et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep. 2016;6(1):37933. doi:10.1038/srep37933.
   PubMedGoogle Scholar
• Li Z, Lai Y, Sun L, Zhang X, Liu R, Feng G, Zhou L, Jia L, Huang X, Kang Q, et al. PD-L1 expression is associated with massive lymphocyte infiltration and histology in gastric cancer. Hum Pathol. 2016;55:182–189. doi:10.1016/j.humpath.2016.05.012.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhu C, Song W, Li J, Zhao G, Cao H. PD-L1 expression and CD8+ T cell infiltration predict a favorable prognosis in advanced gastric cancer. J Immunol Res. 2018;2018:4180517. doi:10.1155/2018/4180517.
   PubMed Web of Science ®Google Scholar
• Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, et al. Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer. 2020;23(1):95–104. doi:10.1007/s10120-019-00999-9.
   PubMed Web of Science ®Google Scholar
• Kim HS, Wu T, Kim H, Chung HC, Ajani JA, Ku GY, Kelsen DP, Zhu X, Savage MJ, Koshiji M, et al. PD-L1 expression in patients with metastatic gastric cancer in South Korea. ABSTRACT J Clin Oncol. 2017;35(15_suppl):1571. doi:10.1200/JCO.2017.35.15_suppl.1571.
   Google Scholar